Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Translational Neurodegeneration
Published in: Translational Neurodegeneration 1/2012

Open Access 01-12-2012 | Review

Neuroimaging in the early diagnosis of neurodegenerative disease

Author: A Jon Stoessl

Published in: Translational Neurodegeneration | Issue 1/2012

Login to get access

Abstract

Functional imaging may be useful for both the early diagnosis as well as preclinical detection of neurodegenerative disease. Additionally, while structural imaging has traditionally been regarded as a tool to exclude alternate diagnoses, recent advances in magnetic resonance show promise for greater diagnostic specificity. The role of MR and radionuclide imaging in early diagnosis and preclinical detection of dementia and parkinsonism are reviewed here.
Literature
1.
Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, et al.: Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011, 21(10):718-79. 10.1016/j.euroneuro.2011.08.008CrossRefPubMed
2.
Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, et al.: Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000, 15(3):503-10. 10.1002/1531-8257(200005)15:3<503::AID-MDS1013>3.0.CO;2-VCrossRefPubMed
3.
Marek K, Seibyl J, Shoulson I, Holloway R, Kieburtz K, McDermott M, et al.: Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002, 287(13):1653-61. 10.1001/jama.287.13.1653CrossRef
4.
Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al.: Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003, 54(1):93-101. 10.1002/ana.10609CrossRefPubMed
5.
Schneider SA, Edwards MJ, Mir P, Cordivari C, Hooker J, Dickson J, et al.: Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord 2007, 22(15):2210-5. 10.1002/mds.21685CrossRefPubMed
6.
Marshall VL, Patterson J, Hadley DM, Grosset KA, Grosset DG: Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nucl Med Commun 2006, 27(12):933-7. 10.1097/01.mnm.0000243374.11260.5bCrossRefPubMed
7.
Marshall VL, Patterson J, Hadley DM, Grosset KA, Grosset DG: Successful antiparkinsonian medication withdrawal in patients with Parkinsonism and normal FP-CIT SPECT. Mov Disord 2006, 21(12):2247-50. 10.1002/mds.21159CrossRefPubMed
8.
Silveira-Moriyama L, Schwingenschuh P, O'Donnell A, Schneider SA, Mir P, Carrillo F, et al.: Olfaction in patients with suspected parkinsonism and scans without evidence of dopaminergic deficit (SWEDDs). J Neurol Neurosurg Psychiatry 2009, 80(7):744-8. 10.1136/jnnp.2009.172825CrossRefPubMed
9.
Schwingenschuh P, Ruge D, Edwards MJ, Terranova C, Katschnig P, Carrillo F, et al.: Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: A clinical and electrophysiological study. Mov Disord 2010.
10.
Brooks DJ, Ibanez V, Sawle GV, Quinn N, Lees AJ, Mathias CJ, et al.: Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990, 28: 547-55. 10.1002/ana.410280412CrossRefPubMed
11.
Antonini A, Leenders KL, Vontobel P, Maguire RP, Missimer J, Psylla M, et al.: Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 1997, 120: 2187-95. 10.1093/brain/120.12.2187CrossRefPubMed
12.
Brucke T, Asenbaum S, Pirker W, Djamshidian S, Wenger S, Wober C, et al.: Measurement of the dopaminergic degeneration in Parkinon's disease with [123I]beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm (Suppl) 1997, 50: 9-24.CrossRef
13.
Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, et al.: The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994, 14(5):783-801. 10.1038/jcbfm.1994.99CrossRefPubMed
14.
Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS, et al.: FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005, 26(3):912-21. 10.1016/j.neuroimage.2005.03.012CrossRefPubMed
15.
Tang CC, Poston KL, Eckert T, Feigin A, Frucht S, Gudesblatt M, et al.: Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol 2010, 9(2):149-58. 10.1016/S1474-4422(10)70002-8PubMedCentralCrossRefPubMed
16.
Yoshita M: Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998, 155(1):60-7. 10.1016/S0022-510X(97)00278-5CrossRefPubMed
17.
Goldstein DS, Holmes C, Bentho O, Sato T, Moak J, Sharabi Y, et al.: Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord 2008, 14(8):600-7. 10.1016/j.parkreldis.2008.01.010PubMedCentralCrossRefPubMed
18.
Braune S, Reinhardt M, Bathmann J, Krause T, Lehmann M, Lucking CH: Impaired cardiac uptake of meta-[123I]iodobenzylguanidine in Parkinson's disease with autonomic failure. Acta Neurol Scand 1998, 97(5):307-14. 10.1111/j.1600-0404.1998.tb05958.xCrossRefPubMed
19.
Raffel DM, Koeppe RA, Little R, Wang CN, Liu S, Junck L, et al.: PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes. J Nucl Med 2006, 47(11):1769-77.PubMed
20.
Schrag A, Good CD, Miszkiel K, Morris HR, Mathias CJ, Lees AJ, et al.: Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000, 54(3):697-702.CrossRefPubMed
21.
Kato N, Arai K, Hattori T: Study of the rostral midbrain atrophy in progressive supranuclear palsy. J Neurol Sci 2003, 210(1-2):57-60. 10.1016/S0022-510X(03)00014-5CrossRefPubMed
22.
Nicoletti G, Lodi R, Condino F, Tonon C, Fera F, Malucelli E, et al.: Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Brain 2006, 129(Pt 10):2679-87.CrossRefPubMed
23.
Nicoletti G, Tonon C, Lodi R, Condino F, Manners D, Malucelli E, et al.: Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson's disease. Mov Disord 2008, 23(16):2370-6. 10.1002/mds.22279CrossRefPubMed
24.
Seppi K, Schocke MF, Esterhammer R, Kremser C, Brenneis C, Mueller J, et al.: Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003, 60(6):922-7.CrossRefPubMed
25.
Morelli M, Arabia G, Novellino F, Salsone M, Giofre L, Condino F, et al.: MRI measurements predict PSP in unclassifiable parkinsonisms: A cohort study. Neurology 2011, 77(11):1042-7. 10.1212/WNL.0b013e31822e55d0CrossRefPubMed
26.
Peran P, Cherubini A, Assogna F, Piras F, Quattrocchi C, Peppe A, et al.: Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 2010, 133(11):3423-33. 10.1093/brain/awq212CrossRefPubMed
27.
Appel J, Potter E, Shen Q, Pantol G, Greig MT, Loewenstein D, et al.: A comparative analysis of structural brain MRI in the diagnosis of Alzheimer's disease. Behav Neurol 2009, 21(1):13-9.CrossRefPubMed
28.
Fukui T, Kertesz A: Volumetric study of lobar atrophy in Pick complex and Alzheimer's disease. J Neurol Sci 2000, 174(2):111-21. 10.1016/S0022-510X(00)00261-6CrossRefPubMed
29.
Firbank MJ, Blamire AM, Krishnan MS, Teodorczuk A, English P, Gholkar A, et al.: Diffusion tensor imaging in dementia with Lewy bodies and Alzheimer's disease. Psychiatry Res 2007, 155(2):135-45. 10.1016/j.pscychresns.2007.01.001CrossRefPubMed
30.
Rombouts SA, van Swieten JC, Pijnenburg YA, Goekoop R, Barkhof F, Scheltens P: Loss of frontal fMRI activation in early frontotemporal dementia compared to early AD. Neurology 2003, 60(12):1904-8.CrossRefPubMed
31.
Greicius MD, Krasnow B, Reiss AL, Menon V: Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci USA 2003, 100(1):253-8. 10.1073/pnas.0135058100PubMedCentralCrossRefPubMed
32.
Greicius MD, Srivastava G, Reiss AL, Menon V: Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA 2004, 101(13):4637-42. 10.1073/pnas.0308627101PubMedCentralCrossRefPubMed
33.
Zhou J, Greicius MD, Gennatas ED, Growdon ME, Jang JY, Rabinovici GD, et al.: Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease. Brain 2010, 133(Pt 5):1352-67.PubMedCentralCrossRefPubMed
34.
Pievani M, de HW, Wu T, Seeley WW, Frisoni GB: Functional network disruption in the degenerative dementias. Lancet Neurol 2011, 10(9):829-43. 10.1016/S1474-4422(11)70158-2PubMedCentralCrossRefPubMed
35.
Jagust W, Reed B, Mungas D, Ellis W, Decarli C: What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 2007, 69(9):871-7. 10.1212/01.wnl.0000269790.05105.16CrossRefPubMed
36.
Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE: Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001, 50(3):358-65. 10.1002/ana.1133CrossRefPubMed
37.
Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, Barbas NR, et al.: FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 2007, 130(Pt 10):2616-35.CrossRefPubMed
38.
O'Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, et al.: Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004, 61(6):919-25. 10.1001/archneur.61.6.919CrossRefPubMed
39.
Hu XS, Okamura N, Arai H, Higuchi M, Matsui T, Tashiro M, et al.: 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies. Neurology 2000, 55(10):1575-7.CrossRefPubMed
40.
Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al.: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004, 55(3):306-19. 10.1002/ana.20009CrossRefPubMed
41.
Rabinovici GD, Furst AJ, O'Neil JP, Racine CA, Mormino EC, Baker SL, et al.: 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007, 68(15):1205-12. 10.1212/01.wnl.0000259035.98480.edCrossRefPubMed
42.
Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C, et al.: Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 2009, 34(1):107-12. 10.1016/j.nbd.2008.12.008CrossRefPubMed
43.
Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, et al.: In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci 2007, 27(39):10365-71. 10.1523/JNEUROSCI.0630-07.2007CrossRefPubMed
44.
Burack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, Cairns NJ: In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 2010, 74(1):77-84. 10.1212/WNL.0b013e3181c7da8ePubMedCentralCrossRefPubMed
45.
Calne DB, Langston JW, Martin WR, Stoessl AJ, Ruth TJ, Adam MJ, et al.: Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature 1985, 317(6034):246-8. 10.1038/317246a0CrossRefPubMed
46.
Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ: The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 1999, 45(5):577-82. 10.1002/1531-8249(199905)45:5<577::AID-ANA5>3.0.CO;2-OCrossRefPubMed
47.
Vingerhoets FJ, Snow BJ, Tetrud JW, Langston JW, Schulzer M, Calne DB: Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol 1994, 36(5):765-70. 10.1002/ana.410360513CrossRefPubMed
48.
Adams JR, van Netten H, Schulzer M, Mak E, McKenzie J, Strongosky A, et al.: PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005, 128(Pt 12):2777-85.CrossRefPubMed
49.
Nandhagopal R, Mak E, Schulzer M, McKenzie J, McCormick S, Sossi V, et al.: Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. Neurology 2008, 71(22):1790-5. 10.1212/01.wnl.0000335973.66333.58PubMedCentralCrossRefPubMed
50.
Sossi V, Fuente-Fernandez R, Nandhagopal R, Schulzer M, McKenzie J, Ruth TJ, et al.: Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. Mov Disord 2010, 25(16):2717-23. 10.1002/mds.23356CrossRefPubMed
51.
Khan NL, Scherfler C, Graham E, Bhatia KP, Quinn N, Lees AJ, et al.: Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology 2005, 64(1):134-6. 10.1212/01.WNL.0000148725.48740.6DCrossRefPubMed
52.
Khan NL, Valente EM, Bentivoglio AR, Wood NW, Albanese A, Brooks DJ, et al.: Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol 2002, 52(6):849-53. 10.1002/ana.10417CrossRefPubMed
53.
Pavese N, Khan NL, Scherfler C, Cohen L, Brooks DJ, Wood NW, et al.: Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: an 18F-dopa PET progression study. Mov Disord 2009, 24(15):2260-6. 10.1002/mds.22817CrossRefPubMed
54.
Binkofski F, Reetz K, Gaser C, Hilker R, Hagenah J, Hedrich K, et al.: Morphometric fingerprint of asymptomatic Parkin and PINK1 mutation carriers in the basal ganglia. Neurology 2007, 69(9):842-50. 10.1212/01.wnl.0000267844.72421.6cCrossRefPubMed
55.
Buhmann C, Binkofski F, Klein C, Buchel C, van ET, Erdmann C, et al.: Motor reorganization in asymptomatic carriers of a single mutant Parkin allele: a human model for presymptomatic parkinsonism. Brain 2005, 128(Pt 10):2281-90.CrossRefPubMed
56.
van Nuenen BF, Weiss MM, Bloem BR, Reetz K, van ET, Lohmann K, et al.: Heterozygous carriers of a Parkin or PINK1 mutation share a common functional endophenotype. Neurology 2009, 72(12):1041-7. 10.1212/01.wnl.0000338699.56379.11PubMedCentralCrossRefPubMed
57.
Ponsen MM, Stoffers D, Booij J, Eck-Smit BL, Wolters EC, Berendse HW: Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004, 56(2):173-81. 10.1002/ana.20160CrossRefPubMed
58.
Berg D, Roggendorf W, Schroder U, Klein R, Tatschner T, Benz P, et al.: Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002, 59(6):999-1005. 10.1001/archneur.59.6.999CrossRefPubMed
59.
Sommer U, Hummel T, Cormann K, Mueller A, Frasnelli J, Kropp J, et al.: Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 2004, 19(10):1196-202. 10.1002/mds.20141CrossRefPubMed
60.
Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J: Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009.
61.
Albin RL, Koeppe RA, Chervin RD, Consens FB, Wernette K, Frey KA, et al.: Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology 2000, 55(9):1410-2.CrossRefPubMed
62.
Iranzo A, Valldeoriola F, Lomena F, Molinuevo JL, Serradell M, Salamero M, et al.: Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 2011, 10(9):797-805. 10.1016/S1474-4422(11)70152-1CrossRefPubMed
63.
Stockner H, Iranzo A, Seppi K, Serradell M, Gschliesser V, Sojer M, et al.: Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder. Mov Disord 2009, 24(13):1906-9. 10.1002/mds.22483CrossRefPubMed
64.
Scherfler C, Frauscher B, Schocke M, Iranzo A, Gschliesser V, Seppi K, et al.: White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: a diffusion-tensor imaging and voxel-based morphometry study. Ann Neurol 2011, 69(2):400-7. 10.1002/ana.22245CrossRefPubMed
65.
Unger MM, Belke M, Menzler K, Heverhagen JT, Keil B, Stiasny-Kolster K, et al.: Diffusion tensor imaging in idiopathic REM sleep behavior disorder reveals microstructural changes in the brainstem, substantia nigra, olfactory region, and other brain regions. Sleep 2010, 33(6):767-73.PubMedCentralPubMed
66.
Killiany RJ, Gomez-Isla T, Moss M, Kikinis R, Sandor T, Jolesz F, et al.: Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol 2000, 47(4):430-9. 10.1002/1531-8249(200004)47:4<430::AID-ANA5>3.0.CO;2-ICrossRefPubMed
67.
Whitwell JL, Przybelski SA, Weigand SD, Knopman DS, Boeve BF, Petersen RC, et al.: 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain 2007, 130(Pt 7):1777-86.PubMedCentralCrossRefPubMed
68.
Karas G, Sluimer J, Goekoop R, van der Flier W, Rombouts SA, Vrenken H, et al.: Amnestic mild cognitive impairment: structural MR imaging findings predictive of conversion to Alzheimer disease. AJNR Am J Neuroradiol 2008, 29(5):944-9. 10.3174/ajnr.A0949CrossRefPubMed
69.
Risacher SL, Saykin AJ, West JD, Shen L, Firpi HA, McDonald BC: Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res 2009, 6(4):347-61. 10.2174/156720509788929273PubMedCentralCrossRefPubMed
70.
Scola E, Bozzali M, Agosta F, Magnani G, Franceschi M, Sormani MP, et al.: A diffusion tensor MRI study of patients with MCI and AD with a 2-year clinical follow-up. J Neurol Neurosurg Psychiatry 2010, 81(7):798-805. 10.1136/jnnp.2009.189639CrossRefPubMed
71.
Dickerson BC, Salat DH, Greve DN, Chua EF, Rand-Giovannetti E, Rentz DM, et al.: Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology 2005, 65(3):404-11. 10.1212/01.wnl.0000171450.97464.49PubMedCentralCrossRefPubMed
72.
De Santi S, de Leon MJ, Rusinek H, Convit A, Tarshish CY, Roche A, et al.: Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001, 22(4):529-39. 10.1016/S0197-4580(01)00230-5CrossRefPubMed
73.
Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY, et al.: Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2000, 97(11):6037-42. 10.1073/pnas.090106797PubMedCentralCrossRefPubMed
74.
de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, et al.: Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 2001, 98(19):10966-71. 10.1073/pnas.191044198PubMedCentralCrossRefPubMed
75.
Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, et al.: Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010, 75(3):230-8. 10.1212/WNL.0b013e3181e8e8b8PubMedCentralCrossRefPubMed
76.
Zhang D, Wang Y, Zhou L, Yuan H, Shen D: Multimodal classification of Alzheimer's disease and mild cognitive impairment. Neuroimage 2011, 55(3):856-67. 10.1016/j.neuroimage.2011.01.008PubMedCentralCrossRefPubMed
77.
Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, et al.: PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007, 68(19):1603-6. 10.1212/01.wnl.0000260969.94695.56CrossRefPubMed
78.
Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, et al.: Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007, 130(Pt 11):2837-44.CrossRefPubMed
79.
Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al.: PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008, 29(10):1456-65. 10.1016/j.neurobiolaging.2007.03.029CrossRefPubMed
80.
Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Nagren K, et al.: Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 2009, 73(10):754-60. 10.1212/WNL.0b013e3181b23564PubMedCentralCrossRefPubMed
81.
Koivunen J, Scheinin N, Virta JR, Aalto S, Vahlberg T, Nagren K, et al.: Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology 2011, 76(12):1085-90. 10.1212/WNL.0b013e318212015eCrossRefPubMed
Metadata
Title
Neuroimaging in the early diagnosis of neurodegenerative disease
Author
A Jon Stoessl
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Translational Neurodegeneration / Issue 1/2012
Electronic ISSN: 2047-9158
DOI
https://doi.org/10.1186/2047-9158-1-5

Other articles of this Issue 1/2012

Translational Neurodegeneration 1/2012 Go to the issue

Review

Advances in the pathogenesis of Alzheimer’s disease: a re-evaluation of amyloid cascade hypothesis

Review

Post subthalamic area deep brain stimulation for tremors: a mini-review

Research

Curcumin inhibition of JNKs prevents dopaminergic neuronal loss in a mouse model of Parkinson’s disease through suppressing mitochondria dysfunction

Review

Current advances in the treatment of Alzheimer's disease: focused on considerations targeting Aβ and tau

Review

Prevention strategies for Alzheimer’s disease

Research

RNAi-mediated knock-down of Dab and Numb attenuate Aβ levels via γ-secretase mediated APP processing